MONTREAL--(Marketwire - January 09, 2009) - TOPIGEN Pharmaceuticals Inc., a clinical-stage
biopharmaceutical company focused on innovative respiratory therapeutics,
today announced that the Company has made strategic additions to its
management team and scientific advisory boards. Robert Boisjoli has been
appointed Chief Financial Officer, bringing more than 20 years of
senior-level finance and management expertise to TOPIGEN, including
experience in both corporate and investment banking roles within the life
sciences and significant experience in business valuation and corporate
"Robert brings to TOPIGEN extensive and diverse financial and operational
management experience," said Mark Parry-Billings, PhD, Chief Executive
Officer of TOPIGEN. "He will play a pivotal role in the Company as we
advance our pipeline of innovative therapeutics for respiratory diseases.
His appointment completes the new management team at TOPIGEN and provides a
significant financial track record in U.S. biotech to supplement the
existing expertise in our business in respiratory product development and
successful licensing in the key North American territory."
Mr. Boisjoli most recently served as Chief Financial Officer and co-founder
of Xanthus Pharmaceuticals Inc., a Boston-based biotechnology company,
where he was responsible for all financial business and operations and was
instrumental in the acquisition of Xanthus by Antisoma, PLC in June 2008.
Prior to this, he was head of Investment Banking in Quebec for various
Canadian securities firms, where most of his activities involved raising
equity for emerging companies in the biotech and information technology
fields. He was also instrumental in setting up a mutual fund primarily
involving smaller capitalization technology firms and was involved in
strategic mergers and acquisitions. He serves on the board of various
companies and professional organizations. Mr. Boisjoli is a Chartered
Accountant and Chartered Business Valuator and holds a Bachelor of Commerce
Degree and a Graduate Diploma in Accountancy from Concordia University.
TOPIGEN Board member Jeremy Curnock Cook added, "TOPIGEN has been able to
attract and secure an international management team to lead the company
based on the strengths of the Company's product portfolio and proprietary
oligonucleotide technology. Dr. Mark Parry-Billings brings significant
expertise in effective respiratory product development, Dr. Lisa Nolan has
led a number of successful and substantial respiratory licensing deals for
both U.S. based and international companies and Robert Boisjoli has just
completed the sale of Boston-based Xanthus to United Kingdom-based
Antisoma. This is truly a focused and expert international team."
In addition, the Company announced strategic additions to its scientific
advisory boards. Marianne Mann, MD, former Deputy Director of the Food and
Drug Administration Division of Pulmonary and Allergy Drug Products, has
been appointed to TOPIGEN's Clinical Advisory Board. TOPIGEN's Research
Advisory Board has also been expanded to include Elizabeth Vadas, PhD,
previously Executive Director of Pharmaceutical Research and Development at
Dr. Parry-Billings added, "We are delighted to welcome these high-level new
appointments to our scientific advisory boards. They add to an already
esteemed group of individuals and will provide significant additional
capabilities and strengths in the areas of regulatory strategy and
pharmaceutical product development."
TOPIGEN Pharmaceuticals is developing a clinical pipeline of innovative
therapeutics for respiratory diseases, including asthma and COPD. The
Company's unique, multi-targeted oligonucleotide product candidates have
compelling therapeutic profiles that address major unmet medical needs.
TOPIGEN's business strategy is to advance products through clinical proof
of concept and out-license to partners for commercialization.